Incretins Receive Pass for Questionable Safety

I think the title of the article says a lot - No Compelling
Evidence Linking Incretin Therapies, Pancreatic Cancer. The
word compelling is characterized by this definition (of an argument,
evidence, etc) convincing. The U.S. Food and Drug Administration
(FDA) and its European counterpart started reviews last year of the
medications, which came on the market less than a decade ago, after a